Document:

EMRISE
CORPORATION

 

CONTINUING
INDEMNIFICATION AGREEMENT

 

This
CONTINUING INDEMNIFICATION AGREEMENT (this “Agreement”) is entered into and effective as of the date
indicated on the signature page hereto (the “Effective Date”) by and between EMRISE Corporation, a Delaware
corporation (the “Company”) and [●], an individual (“Director” and together with the
Company, the “Parties” and each, a “Party”).

 

WHEREAS,
Director is a member of the Company’s Board of Directors (the “Board”) and, in accordance with the Company’s
dissolution plan, the Company desires for Director to resign from [his/her] position as a member of the Board; and

 

WHEREAS,
in order to induce Director to resign from [his/her] position on the Board, the Company seeks to ensure for Director that he will
continue to receive the indemnification he currently receives from the Company as a result of such position as a member of the
Board.

 

NOW
THEREFORE, the Parties, who have had the opportunity to receive independent legal advice in this matter, in consideration
of the mutual covenants and agreements set forth hereinafter, and for other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

 

1.Continued
Indemnification. Subsequent to Director’s resignation from the Board, Director will maintain [his/her] right to
(i) claim or receive indemnification as a director of the Company under any applicable state laws, the Company’s Articles
of Incorporation, the Company’s By-laws, and/or the Indemnification Agreement dated on or about December 8, 2004, any other
indemnity agreement or other agreement entered into between Director and the Company (any such agreement is incorporated herein
by reference) and (ii) claim or receive insurance coverage or be defended under any directors’ insurance coverage which
applies to directors of the Company and which applies to Director in Director’s capacity as a former member of the Board.
Such insurance coverage shall cover any claims made against Director for at least three (3) years following the Effective Date.
In addition, the Director shall receive coverage for six (6) years pursuant to the terms of the Company’s “wind-down”
policy.

 

2.Governing
Law. The laws of the State of New Jersey will govern the interpretation, validity and effect of this Agreement without
regard to principles of conflicts of law, the place of execution or the place for performance thereof. The parties hereto hereby
irrevocably and unconditionally each submits for itself and its property in any legal action or proceeding relating to this Agreement,
or for recognition and enforcement of any judgment in respect thereof, to the exclusive general jurisdiction of the State of New
Jersey and its courts and the courts of the United States of America for the District of New Jersey; consents that any such action
or proceeding shall be brought in such courts, and waives any objection that it may now or hereafter have to the venue of any
such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees
not to plead or claim the same; and agrees that nothing herein shall affect the right to effect service of process in any other
manner permitted by law.

 

    	 	 	 

    	 

    

 

3.Modification.
This Agreement shall not and cannot be modified by any Party by any oral promise or representation made before or after the execution
of this Agreement, and may only be modified by a writing signed by all Parties.

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the day and year written below.

 

	 	EMRISE CORPORATION
	 	 	 
	 	By:
    	                     
	 	Name:	 
	 	Title:	 

 

	Date:
    _______________, 2016	 	 
	 	 	[●],
    an individual

 

[Signature
page to Continued Indemnification Agreement]May
17, 2016

 

To
the Members of the Board of Directors of

EMRISE
Corporation,

 

This
letter shall serve as formal notice of my resignation, effective immediately, from my position as a member of the Board of Directors
of EMRISE Corporation (the “Company”), and all other positions with the Company to which I have been assigned, regardless
of whether I served in such capacity. The resignation is not the result of any disagreement with the Company on any matter relating
to the Company’s operations, polices or practices.

 

Sincerely,

 

	/s/
    Julie Abraham	 
	Julie
    AbrahamMay
17, 2016

 

To
the Members of the Board of Directors of

EMRISE
Corporation,

 

This
letter shall serve as formal notice of my resignation, effective immediately, from my position as a member of the Board of Directors
of EMRISE Corporation (the “Company”), and all other positions with the Company to which I have been assigned, regardless
of whether I served in such capacity. The resignation is not the result of any disagreement with the Company on any matter relating
to the Company’s operations, polices or practices.

 

	Sincerely,	 
	 	 
	/s/
    Otis Baskin	 
	Otis
    BaskinCONTRACT
FOR THE COMPOUNDING OF PHARMACEUTICAL PRODUCTS

 

This
CONTRACT FOR THE COMPOUNDING OF PHARMACEUTICAL PRODUCTS (this “Agreement”) is hereby entered into this 16th day of
May, 2016, by and between Immune Therapeutics, Inc., a corporation organized and currently existing in good standing under the
laws of the State of Florida (“IMUN”), and Complete Pharmacy and Medical Solutions, LLC, a limited liability company
also known as Complete Pharmaceutics and organized and currently existing in good standing under the laws of the State of Florida
(“CPMS”). IMUN and CPMS are sometimes hereinafter referred to individually as a “party” and/or collectively
as the “parties”.

 

WHEREAS,
IMUN has developed a pharmaceutical product designed to enhance the immune system and treat various diseases, including lymphoma,
HIV virus/AIDS, Kaposi Sarcoma, Lymphoma, Ovarian Cancer, Epithelial, Germ Cell Tumor, Low Malignant Potential Tumor, Crohn’s
Disease, Prostate Cancer, Irritable Bowel Syndrome, Pancreatic Cancer, Pancreatic Neuroendoctrine Tumors, Parkinson’s disease,
multiple sclerosis, and herpes. This product is composed of the active drug naltrexone hydrocholoride and can be commercialized
in the form of a tablet, capsule, or as a cream. The product is called LDN. IMUN has the proprietary and legal rights to LDN.
The form of this drug can be modified as agreed to in writing by the parties; and

 

WHEREAS,
CPMS is a pharmacy that specializes in the compounding of a variety of pharmaceutical products, and has the necessary licenses
and permits to compound, import and sell pharmaceutical products. At such time as IMUN obtains the necessary approvals to commercialize
LDN, IMUN will notify CPMS in a timely manner to obtain the necessary permits to produce and commercialize LDN and will provide
the information and documentation for CPMS to obtain these permits; and

 

WHEREAS,
the purpose of this Agreement is to set out the terms and conditions under which CPMS will carry out the services of compounding,
packaging and distributing the LDN tablets, capsules and/or creams (the “LDN-CDS”); and

 

WHEREAS,
the tablets, capsules and creams will be compounded for shipment to patients in the United States or any other areas authorized
by CPMS. In the compounding and packaging process, CPMS must also comply with the United States of America’s Food and Drug
Administration’s (“FDA”) good manufacturing practices (“CGMP”) and those of any regulatory bodies.

 

NOW,
THEREFORE, FOR AND IN CONSIDERATION OF THE RECITALS/WHEREAS CLAUSES SET FORTH ABOVE, WHICH SHALL BE DEEMED AN INTEGRAL PART
OF THIS AGREEMENT AND NOT MERELY RECITALS THERETO, AND FOR $10.00 AND OTHER GOOD AND VALUABLE CONSIDERATION, THE RECEIPT AND SUFFICIENCY
OF WHICH IS HEREBY ACKNOWLEDGED AS RECEIVED BY EACH PARTY FROM THE OTHER, THE PARTIES AGREE AS FOLLOWS:

 

	 	1.	CPMS
    REPRESENTATIONS AND OBLIGATIONS: CPMS hereby represents and agrees as follows:

 

	 	A)	To
have all permits and licenses necessary to carry out the LDN-CDS;
	 	 	 
	 	B)	To
    ship the amounts of compounded LDN ordered by physicians for their patients within thirty (30) days from the day the order
    is received;
	 	 	 
	 	C)	To
    use only the Active Pharmaceutical Ingredients (the “API”) and raw materials that have been previously approved
    by IMUN and only in the amounts that have been previously indicated in writing;
	 	 	 
	 	D)	To
    obtain and pay for an insurance policy that protects the raw materials that are provided by IMUN and the finished LDN tablets,
    capsules and/or creams (the “LDN-P”) against any natural disaster, or destruction of any reasonably insurable
    type (the “Insurance”). The Insurance must at all times protect the goods at the market value of the inventory,
    finished and unfinished goods and raw materials provided by IMUN from time to time, and must name IMUN as an additional loss
    payee;

 

     

     

    

 

	 	E)	To
    allow, upon prior reasonable notice, periodic inspection of the compounding and packaging process to be carried out either
    by IMUN directly or by an agreed to third party on behalf of IMUN;
	 	 	 
	 	F)	To
    order in advance and have shipped directly to CPMS all API for the LDN-CDS and packaging materials for the LDN-P; 
	 	 	 
	 	G)	To
    ensure strict compliance with the CGMP; and
	 	 	 
	 	I)	To
    provide sufficient storage space for the raw materials, ingredients, and packaged products and to protect them from theft,
    flooding or vermin and spoilage and provide the aforementioned Insurance.

 

	 	2.	IMUN’S
    REPRESENTATIONS AND OBLIGATIONS: IMUN hereby represents and agrees as follows:

 

	 	A)	To
    provide sales and marketing assistance necessary to allow CPMS to fulfill its obligations;
	 	 	 
	 	B)	CPMS
    and IMUN agree that under the authorization of IMUN and IMUN’s patents, CPMS shall order and have shipped directly to
    CPMS the API necessary for the production of the LDN-CDS and CPMS shall submit a purchase order for such API to IMUN. IMUN
    shall pay such purchase order directly to the supplier of the API by sending funds by wire transfer to such supplier within
    three (3) business days of receipt of such purchase order. Notwithstanding the foregoing, upon CPMS receiving a minimum of
    10,000 orders (prescriptions) per month (a “10K Month”), CPMS will pay for the API for each such 10K Month; 
	 	 	 
	 	C)	The
    rights provided to CPMS herein to provide the LDN-CDS and produce the LDN-P, are exclusive only to CPMS and will not be provided
    to any other party or entity during the term of this Agreement; 
	 	 	 
	 	D)	To
    provide CPMS with specifications for raw materials and the LDN-P;
	 	 	 
	 	E)	To
    provide CPMS with the necessary technical specifications for the compounding and packaging processes of the LDN-P, as available;
	 	 	 
	 	F)	In
    the event this Agreement is terminated by IMUN for any reason, to reimburse CPMS for all unused packaging materials for the
    LDN-P, which unused packaging materials CPMS will provide to IMUN; 
	 	 	 
	 	G)	To
    pay CPMS, all agreed upon amounts, in a timely manner (within 10 days of receipt of an invoice from CPMS);
	 	 	 
	 	H)	In
    the event that CPMS does not receive and ship at least 1,000 orders (prescriptions), to reimburse CPMS for 100% of the “ramp
    up costs” of providing the LDN-CDS and producing the LDN-P, even in the case where IMUN cancels/terminates this Agreement,
    which provision shall survive the cancellation/termination of this Agreement (for purposes of this Agreement, “ramp
    up costs” are defined as all costs and expenses of labor and materials related to the testing, and required FDA and
    other governmental documentation/approvals of test data); 
	 	 	 
	 	I)	To
    assign a person from IMUN, agreeable to both parties, to be in charge of communication between IMUN and CPMS; 
	 	 	 
	 	J)	To
    provide the design of the secondary packing and the instructions in any language IMUN needs; and
	 	 	 
	 	K)	To
    submit all marketing materials to CPMS for review and approval and such marketing materials must be reviewed and approved
    by CPMS in writing. 

 

     

     

    

 

	 	3.	CPMS
    agrees that:

 

	 	A)	The
    raw materials provided for the LDN-CDS are to be used strictly for the compounding and packaging process of LDN and may under
    no circumstance be sold, transferred, or create a lien over, unless IMUN has given prior written consent for such sale, transfer
    or lien;
	 	 	 
	 	B)	Under
    no circumstances will CPMS sell a pharmaceutical product containing the same formula and technical specifications as those
    used to manufacture and produce LDN; and/or
	 	 	 
	 	C)	CPMS
    will not share, license, or otherwise transfer the formula or technical specifications for the manufacturing of LDN.

 

	 	4.	QUALITY
    CONTROL: IMUN will have the right, upon reasonable prior notice and at IMUN’s own cost and expense, to carry out quality
    audits or to consent through an agreed to third party to inspect the compounding and packaging processes. IMUN may solicit
    any quality certificate from CPMS that may be required by the regulatory bodies of the United States, as it relates to the
    LDN-P.
	 	 	 
	 	5.	TERM.
    This Agreement will have an initial term of three (3) years starting on the date of execution by all parties. The parties
    may agree to extend the term of this Agreement for one (1) year under the same terms and conditions, which agreement shall
    be made in writing, and executed at least sixty (60) days before the expiration of this Agreement.
	 	 	 
	 	6.	EARLY
    TERMINATION: The parties can terminate this Agreement under any of the following circumstances:

 

	 	A)	Mutual
    agreement, in writing,
	 	 	 
	 	B)	Either
    party may terminate this Agreement if the other party fails to materially comply with any of the material obligations that
    are to be fulfilled hereunder. In such an event, the nonbreaching party shall give written notice of such breach and the other
    party shall have thirty (30) days to cure same before the termination is final. In case of early termination by IMUN, CPMS
    will return any and all raw materials, finished products, patents, documents containing technical information, and any other
    property that belongs to IMUN and complete all existing LDN purchase orders before termination, so long as IMUN simultaneously
    reimburses CPMS for all costs, expenses and profit related to same.

 

	 	7.	PAYMENT:
    CPMS will pay IMUN for every tablet or capsule it manufactures, packages and thereafter sells, calculated in accordance with
    the attached Exhibit “A” Payment Terms and Conditions, which Exhibit A is incorporated into this Agreement by
    this reference. Reconciliation and payment for each week (ending Friday) will be made by the following Wednesday.

 

	 	To
    enable IMUN to reconcile amounts paid weekly in accordance with this section 7, CPMS will provide IMUN with the following
    information on a per batch basis:
	 	 
	 	(a)
    A list of all invoices evidencing shipments that occurred for the subject batch, showing the number of the tablets, capsules
    and/or creams that were compounded and shipped to patients, and the prices paid by patients; and
	 	 
	 	(b)
    A list of all shipping costs incurred by CPMS to make the shipments in (a) above, together with copies of invoices or statements
    provided by the shipping vendor; provided, however, that if CPMS receives a 10K Month, CPMS will not be required to provide
    the information in 7 (a) and (b) above for that 10-K Month. 

 

     

     

    

 

	 	IMUN
    shall have the right, upon reasonable prior notice and at IMUN’s own cost and expense, to carry out periodic audits
    to verify that all amounts owed to IMUN have been paid.
	 	 
	 	If
    during the term of this Agreement, the costs for manufacturing and packaging should increase, CPMS shall inform IMUN in writing
    within no more than sixty (60) days of such increase (the “Increase Notice”), at which time both parties shall,
    within 10 days of the date of such Increase Notice, reach a new agreement on pricing in the form of an addendum or CPMS may
    immediately terminate this Agreement without any further notice or cure period.

 

	 	8.	ASSIGNMENT:
    Neither party may, under any circumstances, assign this Agreement, either totally or partially, nor the rights contained herein
    without the prior written consent of the other party and the assignee’s assumption of all of the obligations of the
    assignor as set forth herein.
	 	 	 
	 	9.	LABOR
    RELATIONSHIP: This Agreement does not create any type of labor relationship between IMUN and the employees of CPMS. Therefore,
    CPMS and IMUN will be solely responsible for paying any and all wages, indemnifications, insurance policies, or any other
    payment due to its employees in accordance with all labor laws, any internal regulation and any trade union agreement, if
    one were to exist. 
	 	 	 
	 	10.	NONDISCLOSURE:
    “Confidential Information” shall be defined as any nonpublic information disclosed by one party to the other party
    and shall be deemed to include the following information of the respective parties, without limitation: (a) e-mail addresses,
    customer lists, the names of customer contacts, the names of investor contacts, investor lists, professional contacts, business
    plans, technical data, product ideas, personnel, contracts and financial information; (b) patents, trade secrets, techniques,
    processes, business methodologies, schematics, employee suggestions, development tools and processes, computer printouts,
    computer programs, design and drawings and manuals, and improvements; (c) information about costs, profits, markets and sales;
    (d) plans for future development and new product concepts; (e) all documents, books, papers, drawings, models, sketches, graphic
    design, photographs, type fonts, topographical treatments and text, illustrations, visual designs, animation, sound, visual
    elements, prints and other data of any kind and description, including electronic data recorded or retrieved by any means,
    that have been or will be disclosed, as well as written or oral instructions or comments.
	 	 	 
	 	 	Notwithstanding
    the foregoing, Confidential Information of a party shall not include information that (i) has become public knowledge through
    legal means without fault by the receiving party, (ii) is already public knowledge prior to the disclosure of the Confidential
    Information by the party disclosing Confidential Information (“Disclosing Party”) to the party receiving Confidential
    Information (“Receiving Party”), (iii) is known to the Receiving Party prior to Disclosing Party’s disclosure
    of the same pursuant to this Agreement, or (iv) is independently developed by the Receiving Party without reference to or
    use of the Confidential Information.

 

     

     

    

 

	 	 	In
    the performance of this Agreement or in contemplation thereof, each party and its employees and agents may have access to
    Confidential Information owned or controlled by the other party. All Confidential Information supplied by one party to the
    other shall remain the exclusive property of the party supplying same. The Receiving Party shall use a reasonable degree of
    care, which in any event shall not be less than the same degree of care which the Receiving Party uses to protect its own
    proprietary and confidential information, to keep, and have its employees and agents keep, confidential any and all Confidential
    Information. In keeping therewith, the recipient shall not copy or publish or disclose the Confidential Information to others,
    or authorize its employees, or agents or anyone else to copy, publish or disclose it to others, without the Disclosing Party’s
    written approval, nor shall the Receiving Party make use of the Confidential Information except for the purposes of executing
    its obligations under this Agreement, and shall return the Confidential Information to the Disclosing Party at its request.
	 	 	 
	 	 	Without
    limiting the preceding paragraph, each party recognizes and acknowledges that:

 

	 	(i) the Confidential Information is a valuable, special and unique asset of the Disclosing Party and that disclosure of any confidential information would cause considerable harm to the Disclosing Party’s business reputation;
	 	 
	 	(ii) it is vital to the Disclosing Party’s legitimate business interests that (1) the confidentiality of the Confidential information be preserved and (2) the Confidential information only be used for the purpose of this Agreement;
	 	 	 
	 	(iii) disclosure of the Confidential Information to any other person or entity or use of the Confidential Information by or on behalf of any other person or entity could result in irreparable harm to the Disclosing Party;
	 	 	 
	 	(iv) disclosure or use beyond the permitted scope of Confidential Information entrusted to the Disclosing Party by its clients and contractors could expose Disclosing Party to substantial damages; and
	 	 	 
	 	(v) Receiving Party shall not use or in any way implement the Confidential Information to compete with the Disclosing Party.

 

	 	 	The
    furnishing of Confidential Information hereunder shall not constitute or be construed as a grant of any express or implied
    license or other right, or a covenant not to sue or forbearance from any other right of action (except as it relates to the
    purpose of this Agreement), by Disclosing Party under any of its patents or other intellectual property rights.

 

	 	11.	INTELLECTUAL
    PROPERTY RIGHTS AND USE OF INFORMATION: All trademarks, US and foreign patents and extensions thereof, trade secrets, formulas,
    ideas, designs, computer software, discoveries and procedures used or disclosed by IMUN in relation to the services agreed
    upon in this Agreement are owned exclusively by IMUN and may be used only in relation to the manufacturing and packaging processes
    described herein. Unless otherwise in the public domain, they may be given no other use unless there is prior written consent
    by IMUN.
	 	 	 
	 	12.	FORCE
    MAJEURE: For purposes of this Agreement, “Force Majeure” shall mean a cause or event that is not reasonably foreseeable
    or prevented or otherwise caused by or under the control of the party, such as floods, wars and riots. If a case of Force
    Majeure were to arise which materially affects the duties or obligations of a party, the party affected by it must inform
    the other party in writing of its occurrence within three (3) business days. In that case, both parties may then agree on
    one of the following:

 

     

     

    

 

	 	A)	To
    continue to carry out this Agreement under the same terms and conditions, making provision for compliance subject to the issues
    affected by the Force Majeure;
	 	 	 
	 	B)	To
    continue to carry out this Agreement under new conditions;
	 	 	 
	 	C)	To
    terminate this Agreement without any further obligations;
	 	 	 
	 	D)	If
    no agreement is reached, this Agreement may be terminated by the party to whom the duties or obligations are due, after proper
    notice and time to cure regarding a default (as set forth in this Agreement).

 

	 	13.	CONFLICT
    RESOLUTION: This Agreement shall be governed by, construed and enforced in accordance with the laws of the jurisdiction in
    the State of Florida. Any dispute that the parties cannot resolve through mediation must submit to arbitration. Such arbitration
    shall be arbitrated in Palm Beach County, Florida, whether commenced by IMUN or CPMS, in accordance with the applicable rules
    of the American Arbitration Association, Commercial Dispute Resolution Procedures, and judgment on the award rendered by the
    arbitrator(s) shall be binding on the parties and may be entered in any court having jurisdiction.
	 	 	 
	 	14.	REVISION
    AND MODIFICATIONS TO THIS AGREEMENT: The parties agree to revise this Agreement, on an annual basis. Any modification that
    may be agreed upon must be done in writing signed by the parties and in the form of an addendum and will be considered part
    of this Agreement.
	 	 	 
	 	15.	MISCELLANEOUS:

 

	 	A)	Subject
    to applicable law, this Agreement may be amended, modified, or supplemented only by a written agreement signed by parties.
	 	 	 
	 	B)	Any
    failure of any party to comply with any obligation, covenant, agreement, or condition herein may be waived by the party entitled
    to the performance of such obligation, covenant, or agreement or who has the benefit of such condition, but such waiver or
    failure to insist upon strict compliance with such obligation, covenant, agreement, or condition will not operate as a waiver
    of, or estoppel with respect to, any subsequent or other failure. Whenever this Agreement requires or permits consent by or
    on behalf of any party hereto, such consent will be given in a manner consistent with the requirements for a waiver of compliance
    as set forth above. 
	 	 	 
	 	C)	All
    notices, requests, demands, and other communications required or permitted hereunder will be in writing and will be deemed
    to have been duly given when delivered by hand, or one day when sent overnight by a nationally recognized overnight delivery
    service (such as FEDEX), or two days after being mailed by certified or registered mail, return receipt requested, with postage
    prepaid:

 

	If
    to IMUN:	Immune
    Therapeutics, Inc. 
	 	37
    North Orange Ave., Suite 607
	 	Orlando,
    Florida 32801 
	 	Attention:
    General Counsel
	 	 
	If
    to the CPMS:	Complete
    Pharmacy and Medical Solutions, LLC
	 	5829
    NW 158th Street 
	 	Miami
    Lakes, Florida 33014
	 	Attention:
    Dr. Gregory G. Gaiser

 

or
to such other address as the parties may furnish to each other in writing.

 

     

     

    

 

	 	D)	All
    section titles or captions contained in this Agreement are for convenience only and shall not be deemed part of the context
    nor effect the interpretation of this Agreement.
	 	 	 
	 	E)	This
    Agreement contains the entire understanding between and among the parties and supersedes any prior understandings and agreements
    among them respecting the subject matter of this Agreement. 
	 	 	 
	 	F)	This
    Agreement shall be binding upon the heirs, executors, administrators, successors and assigns of the parties hereto.
	 	 	 
	 	G)	In
    the event an arbitration is brought by any party under this Agreement to enforce any of its terms, or in any appeal therefrom,
    it is agreed that the prevailing party shall be entitled to reasonable attorneys’ fees to be fixed by the arbitrator
    and/or appellate court.
	 	 	 
	 	H)	In
    computing any period of time pursuant to this Agreement, the day of the act, event or default from which the designated period
    of time begins to run shall be included, unless it is a Saturday, Sunday, or a legal holiday, in which event the period shall
    begin to run on the next day which is not a Saturday, Sunday, or legal holiday, in which event the period shall run until
    the end of the next day thereafter which is not a Saturday, Sunday, or legal holiday.
	 	 	 
	 	I)	All
    pronouns and any variations thereof shall be deemed to refer to the masculine, feminine, neuter, singular, or plural as the
    identity of the person or persons may require.
	 	 	 
	 	J)	This
    Agreement or any section thereof shall not be construed against any party due to the fact that said Agreement or any section
    thereof was drafted by said party.
	 	 	 
	 	K)	The
    parties hereto shall execute and deliver all documents, provide all information and take or forbear from all such action as
    may be necessary or appropriate to achieve the purposes of the Agreement.
	 	 	 
	 	L)	Nothing
    herein shall be construed to be to the benefit of any third party, nor is it intended that any provision shall be for the
    benefit of any third party.
	 	 	 
	 	M)	If
    any provision of this Agreement, or the application of such provision to any person or circumstance, shall be held invalid,
    the remainder of this Agreement, or the application of such provision to persons or circumstances other than those as to which
    it is held invalid, shall not be affected thereby. 

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date set forth above.

 

	Immune
Therapeutics, Inc. 	 	Complete Pharmacy and Medical Solutions, LLC

 

	By:		 	By:	
	 	Noreen
    Griffin, CEO	 	 	Dr.
    Gregory G. Gaiser, Managing Member

 

     

     

    

 

Exhibit
“A” Payment Terms and Conditions

 

Net
Distributable Revenue Calculation (30 day supply) Without Blister Pack:

 

	Gross
    Revenue (excluding actual shipping costs)	 	(A)
	 	 	 
	Less
    API Cost .06 Per Tablet (Advanced by IMUN)	 	(B)
	 	 	 
	Less
    CC Charges (Advanced by CPMS)	 	(C)
	 	 	 
	Credit
    Card Charge @ 2.5% (calculated with shipping charge)	 	 
	Total
    Per Order	 	 
	 	 	 
	Net
    Distributable Revenue	 	(D)

 

*Shipping
Charge of a flat $10.00 for ground will be collected and retained by CPMS. Additional charge for overnight shipping will be determined
based on patient zip codes.

 

IMUN
Reimbursement Calculation:

 

	API
    Reimbursement	 	(B)
	50%
    of Net Distributable Revenue 	 	(D)
	 	 	 
	Due
    to IMUN	 	Total
    of B&D

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]